JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB92637

Recombinant human Tissue Plasminogen Activator protein, Two Chain (Active)

Be the first to review this product! Submit a review

|

(8 Publications)

Recombinant human Tissue Plasminogen Activator protein, Two Chain (Active) is a Human Full Length protein, in the 36 to 562 aa range, expressed in CHO cells, with >95%, suitable for SDS-PAGE, FuncS.

View Alternative Names

Tissue-type plasminogen activator, t-PA, t-plasminogen activator, tPA, PLAT

1 Images
SDS-PAGE - Recombinant human Tissue Plasminogen Activator protein, Two Chain (Active) (AB92637)
  • SDS-PAGE

Unknown

SDS-PAGE - Recombinant human Tissue Plasminogen Activator protein, Two Chain (Active) (AB92637)

10% SDS-PAGE
Lane 1 : TPA Tissue Plasminogen Activator (3 ug) Non-reduced
Lane 2 : TPA Tissue Plasminogen Activator (3 ug) Reduced
Lane 3 : Prestained Standard

Key facts

Purity

>95% SDS-PAGE

Expression system

CHO cells

Tags

Tag free

Applications

SDS-PAGE, FuncS

applications

Biologically active

Yes

Biological activity

3,147,288 IU/mg (Relative to WHO International Standard for Human Recombinant Tissue Plasminogen Activator, NIBSC 98/714).

Accession

P00750

Animal free

No

Carrier free

No

Species

Human

Storage buffer

pH: 7.4 Constituents: 9.52% HEPES, 0.58% Sodium chloride

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "FuncS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Extinction Coefficient: 1.9

Sequence info

[{"linker":null,"sequence":"SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP","proteinLength":"Full Length","predictedMolecularWeight":"59.04 kDa","actualMolecularWeight":null,"aminoAcidEnd":562,"aminoAcidStart":36,"nature":"Recombinant","expressionSystem":"CHO cells","accessionNumber":"P00750","tags":[]}]

Properties and storage information

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
True

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Tissue Plasminogen Activator (tPA) also known as a plasminogen activator acts mechanically to convert plasminogen to plasmin a serine protease. This reaction occurs at the surface of a fibrin clot leading to clot degradation a process known as fibrinolysis. tPA has a molecular mass of approximately 70 kDa. It is mainly expressed in vascular endothelial cells and is released into the bloodstream in response to stimuli such as circulatory stasis or endothelial damage.
Biological function summary

TPA plays a critical role in thrombolysis by breaking down blood clots into their soluble components. It regulates plasminogen function by cleaving this zymogen to yield the active protease plasmin. This function makes tPA integral in maintaining hemostasis and it does not form a part of a larger protein complex. The activity and the regulation of tPA are important for preventing pathologic clotting which can lead to cardiovascular complications.

Pathways

TPA is central to the fibrinolytic pathway. This pathway facilitates the conversion of plasminogen to plasmin enabling clot resolution. In addition tPA interacts with other proteins such as urokinase plasminogen activator (uPA) and inhibitors like plasminogen activator inhibitor-1 (PAI-1). The balance between tPA and its inhibitors is important for the regulation of fibrinolytic activity impacting hemostatic and thrombotic events.

TPA connects closely with conditions like stroke and myocardial infarction due to its thrombolytic properties. In ischemic stroke excessive or insufficient tPA activity can disrupt normal blood flow leading to tissue damage. Additionally in myocardial infarction tPA's role in breaking down clots proves important for restoring coronary blood flow. It is also linked with proteins like fibrinogen as they serve as substrates in the clot degradation process and with PAI-1 which modulates its activity and influences disease progression.

Specifications

Form

Liquid

Additional notes

Activated from single-chain form with immobilized plasmin. 100% complex formation with Human PAI1.

General info

Function

Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. During oocyte activation, plays a role in cortical granule reaction in the zona reaction, which contributes to the block to polyspermy (By similarity).

Sequence similarities

Belongs to the peptidase S1 family.

Post-translational modifications

The single chain, almost fully active enzyme, can be further processed into a two-chain fully active form by a cleavage after Arg-310 catalyzed by plasmin, tissue kallikrein or factor Xa.. Differential cell-specific N-linked glycosylation gives rise to two glycoforms, type I (glycosylated at Asn-219) and type II (not glycosylated at Asn-219). The single chain type I glycoform is less readily converted into the two-chain form by plasmin, and the two-chain type I glycoform has a lower activity than the two-chain type II glycoform in the presence of fibrin.. N-glycosylation of Asn-152; the bound oligomannosidic glycan is involved in the interaction with the mannose receptor.. Characterization of O-linked glycan was studied in Bowes melanoma cell line.

Product protocols

Target data

Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. During oocyte activation, plays a role in cortical granule reaction in the zona reaction, which contributes to the block to polyspermy (By similarity).
See full target information PLAT

Publications (8)

Recent publications for all applications. Explore the full list and refine your search

Nature communications 16:3705 PubMed40251193

2025

Covalently reactive microparticles imbibe blood to form fortified clots for rapid hemostasis and prevention of rebleeding.

Applications

Unspecified application

Species

Unspecified reactive species

Ting Chen,Chaonan Xiao,Xianjun Chen,Ziyi Yang,Jingwei Zhao,Bingkun Bao,Qingmei Zeng,Li Jiang,Xinyi Huang,Yi Yang,Qiuning Lin,Wei Gong,Linyong Zhu

Research and practice in thrombosis and haemostasis 8:102291 PubMed38222077

2024

Fluorescent peptide for detecting factor XIIIa activity and fibrin in whole blood clots forming under flow.

Applications

Unspecified application

Species

Unspecified reactive species

Yue Liu,Jennifer Crossen,Timothy J Stalker,Scott L Diamond

Journal of lipid research 64:100441 PubMed37666362

2023

Decoding the role of angiopoietin-like protein 4/8 complex-mediated plasmin generation in the regulation of LPL activity.

Applications

Unspecified application

Species

Unspecified reactive species

Yan Q Chen,Eugene Y Zhen,Anna M Russell,Mariam Ehsani,Robert W Siegel,Yuewei Qian,Robert J Konrad

International journal of molecular sciences 23: PubMed36499270

2022

1,2,3-Triazole Derivatives as Novel Antifibrinolytic Drugs.

Applications

Unspecified application

Species

Unspecified reactive species

Oriol Bosch-Sanz,Yvette Rabadà,Xevi Biarnés,Javier Pedreño,Luis Caveda,Mercedes Balcells,Jordi Martorell,David Sánchez-García

Science advances 8:eabn2627 PubMed35584211

2022

Reduced platelet forces underlie impaired hemostasis in mouse models of -related disease.

Applications

Unspecified application

Species

Unspecified reactive species

Juliane Baumann,Laura Sachs,Oliver Otto,Ingmar Schoen,Peter Nestler,Carlo Zaninetti,Martin Kenny,Ruth Kranz,Hendrik von Eysmondt,Johanna Rodriguez,Tilman E Schäffer,Zoltan Nagy,Andreas Greinacher,Raghavendra Palankar,Markus Bender

Frontiers in cell and developmental biology 8:564351 PubMed33282858

2020

Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Is a Negative Regulator of Oligodendrocyte Progenitor Cell Differentiation in the Adult Mouse Brain.

Applications

Unspecified application

Species

Unspecified reactive species

Loic Auderset,Kimberley A Pitman,Carlie L Cullen,Renee E Pepper,Bruce V Taylor,Lisa Foa,Kaylene M Young

OncoTargets and therapy 10:2077-2085 PubMed28442916

2017

Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors.

Applications

Unspecified application

Species

Unspecified reactive species

John H Rossmeisl,Kelli Hall-Manning,John L Robertson,Jamie N King,Rafael V Davalos,Waldemar Debinski,Subbiah Elankumaran

Theranostics 5:267-76 PubMed25553114

2015

Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers.

Applications

Unspecified application

Species

Unspecified reactive species

Qing Kay Li,Li Chen,Ming-Hui Ao,Joyce Hanching Chiu,Zhen Zhang,Hui Zhang,Daniel W Chan
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com